- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.10. | There Is No Such Thing as a Typical Biotech | ||
| 02.10. | Novartis pens $7.8B deal for Abogen's in vivo autoimmune TCE | ||
| 02.10. | Bayer taps new chief medical officer-Chutes & Ladders | ||
| 02.10. | NAMs: Why proving repeatability is the next hurdle for widespread adoption | ||
| 02.10. | Adecto blames 'risk-adverse funding environment' for closing | ||
| 01.10. | Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 | ||
| 01.10. | Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D | ||
| 30.09. | Lilly raises diabetes weight loss bar with amylin-Zepbound combo | ||
| 30.09. | Beam Therapeutics sues base editing rival, claims former scientist stole secrets | ||
| 30.09. | Merck's anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial | ||
| 30.09. | GSK continues to stock up on Wave's RNA drugs with liver-focused program | ||
| 30.09. | Connect's Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal | ||
| 30.09. | Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody | ||
| 30.09. | Roche, Zealand Pharma see phase 2 amylin weight loss peak at mid-dose, start pivotal program | ||
| 30.09. | Lilly sets up next-gen obesity battle with full phase 3 retatrutide data | ||
| 29.09. | Enanta sheds staffers as key antiviral, immunology readouts loom | ||
| 29.09. | uniQure stock crashes as Huntington's gene therapy data weaken | ||
| 29.09. | Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui | ||
| 29.09. | AstraZeneca scales Summit's PD-1xVEGF strategy with $2B investment to fuel ADC combos | ||
| 28.09. | Roche drops muscle-sparing obesity antibody after flunked interim analysis | ||
| 28.09. | Mirum posts phase 3 hepatitis win for 'commercially differentiated' challenger to Gilead, Vir | ||
| 28.09. | Scynexis bags $214M BARDA contract for antifungal development | ||
| 28.09. | Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3 | ||
| 28.09. | Merck pens $2.1B deal with China's SciBrunch to chase KRAS G12D | ||
| 28.09. | Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.